Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Mirati Therapeutics Reports First Quarter Financial Results
SAN DIEGO , May 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage oncology company, today reported financial results for the first quarter ended March 31, 2018 . "We have made significant progress in all of our programs and continue to be encouraged by positive
View HTML
Toggle Summary Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
- Six Partial Responses achieved to date in first 23 evaluable patients receiving the combination of sitravatinib and nivolumab for the treatment of checkpoint inhibitor refractory non-small cell lung cancer -- Tumor reductions observed in 19 of 23 evaluable patients -- 45 patients have been
View HTML
Toggle Summary Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results
SAN DIEGO , March 8, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, today reported financial results for the fourth quarter and full-year ended December 31, 2017 . "We made significant progress in our key programs in 2017," said
View HTML
Toggle Summary Mirati Therapeutics To Present At Upcoming Healthcare Conferences
SAN DIEGO , March 7, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at three upcoming healthcare conferences. Cowen 38 th Annual Healthcare Conference on Wednesday, March 14 th at 9:20 a.m. ET / 6:20 a.m. PT .
View HTML
Toggle Summary Mirati Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare Conference
SAN DIEGO , Feb. 8, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology biotechnology company, will participate in the Leerink Partners 7 th Annual Global Healthcare Conference in New York on Thursday, February 15 th at 2:30 p.m. ET / 11:30 a.m. PT .
View HTML
Toggle Summary BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region View HTML
Toggle Summary Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , Nov. 20, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the closing of its previously announced underwritten public offering of 2,938,986 shares of its common stock at a public offering price of $13.00 per share.
View HTML
Toggle Summary Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO , Nov. 16, 2017 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 2,015,901 shares of its common stock at a price to the public of $13.00 per share. In addition, and in lieu of common stock, Mirati is offering to
View HTML
Toggle Summary Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
SAN DIEGO , Nov. 15, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of
View HTML
Toggle Summary Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs
- Sitravatinib immuno-oncology program to be accelerated following encouraging clinical efficacy data previously reported for sitravatinib in combination with nivolumab - KRAS program advances with orally-active, mutation-selective clinical lead and backups; IND submission anticipated in 2018 -
View HTML